Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies

Hsin Yi Tung, Yu Cheng Su, Bing Mae Chen, Pierre Alain Burnouf, Wei Chiao Huang, Kuo Hsiang Chuang, Yu Ting Yan, Tian Lu Cheng, Steve R. Roffler

研究成果: 雜誌貢獻文章同行評審

23 引文 斯高帕斯(Scopus)

摘要

Polyethylene glycol (PEG) is attached to many peptides, proteins, liposomes, and nanoparticles to reduce their immunogenicity and improve their pharmacokinetic and therapeutic properties. Here, we describe hybrid antibodies that can selectively deliver PEGylated medicines, imaging agents, or nanomedicines to target cells. Human IgG1 hybrid antibodies αPEG:αHER2 and αPEG:a CD19were shown by ELISA, FACS, and plasmonresonance to bind to both PEG and HER2 receptors on SK-BR-3 breast adenocarcinoma and BT-474 breast ductal carcinoma cells or CD19 receptors on Ramos and Raji Burkitt's lymphoma cells. In addition, αPEG:α HER2 specifically targeted PEGylated proteins, liposomes, and nanoparticles to SK-BR-3 cells that overexpressed HER2, but not toHER2-negativeMCF-7 breast adenocarcinoma cells. Endocytosis of PEGylated nanoparticles into SK-BR-3 cells was induced specifically by the αPEG:αHER2 hybrid antibody, as observed by confocal imaging of the accumulation of Qdots inside SK-BR-3 cells. Treatment of HER2+ SK-BR-3 and BT-474 cancer cells with αPEG:α HER2 and the clinically used chemotherapeutic agent PEGylated liposomal doxorubicin for 3 hours enhanced the in vitro effectiveness of PEGylated liposomal doxorubicin by over two orders of magnitude. Hybrid anti-PEG antibodies offer a versatile and simple method to deliver PEGylated compounds to cellular locations and can potentially enhance the therapeutic efficacy of PEGylated medicines.

原文英語
頁(從 - 到)1317-1326
頁數10
期刊Molecular Cancer Therapeutics
14
發行號6
DOIs
出版狀態已發佈 - 六月 1 2015

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies」主題。共同形成了獨特的指紋。

引用此